• Guidance
  • Interesting shortcuts
  • EFFRA Members' Perspectives
  • News Dashboard
  • Structured Wiki
    • Search
    • FoF and Made in Europe Partnership
    • Demonstrators, pilots, prototypes
    • Exploitable result(s)
    • Significant innovations and lessons learned, training aspects
    • Report - Video - Presentation - Publication....?
    • Project clusters
    • EFFRA member perspectives
    • Manufacturing future products
    • Manufacturing performance characteristics
    • Technologies and enablers
    • ICT performance characteristics
    • Standards, technical committees and working groups
    • Contribution of R&I projects to standardisation
    • Regulatory and policy aspects
    • Standards - other classifications
    • Business model aspects
    • Pathways
    • MiE SRIA R&I Priorities
    • MiE WP26-27 Consultation - Potential Research Topics only
    • MiE WP26-27 Consultation and context pointers
    • MiE WP26-27 Consultation with pointers to WP25-27 consultation
    • MiE KPIs
    • Relevant (future) calls
    • EU-Programme-Call
    • NACE code
    • EFFRA Organisations - members
    • EFFRA WG pointers
  • Pathways
    • Pathways
  • Projects
    • Projects
  • Resources
    • Resources
  • Project ideas
    • Project ideas
  • People & organisations
    • People
    • Organisations
  • portal@effra.eu
  • Visit the EFFRA website
    • Login
  • Structured Wiki
  • EU-Programme-Call
  • Horizon 2020
  • H2020-EU.3. SOCIETAL CHALLENGES
  • H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
  • H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)

H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)

  • H2020-EU.3.1.7.0. Cross-cutting call topics
    • H2020-JTI-IMI2-2014-01-two-stage
    • H2020-JTI-IMI2-2014-02-single-stage
    • H2020-JTI-IMI2-2015-03-two-stage
    • H2020-JTI-IMI2-2015-05-two-stage
    • H2020-JTI-IMI2-2015-06-two-stage
    • H2020-JTI-IMI2-2015-07-two-stage
    • H2020-JTI-IMI2-2015-08-single-stage
    • H2020-JTI-IMI2-2016-09-two-stage
    • H2020-JTI-IMI2-2016-10-two-stage
    • H2020-JTI-IMI2-2017-11-single-stage
    • H2020-JTI-IMI2-2017-12-two-stage
    • H2020-JTI-IMI2-2017-13-two-stage
    • H2020-JTI-IMI2-2018-14-two-stage
    • H2020-JTI-IMI2-2018-15-two-stage
    • H2020-JTI-IMI2-2018-16-single-stage
    • H2020-JTI-IMI2-2019-17-two-stage
    • H2020-JTI-IMI2-2019-18-two-stage
    • H2020-JTI-IMI2-2019-19-single-stage
    • H2020-JTI-IMI2-2020-21-single-stage
  • H2020-EU.3.1.7.1. Antimicrobial resistance
  • H2020-EU.3.1.7.12. Vaccine
    • H2020-JTI-IMI2-2015-03-two-stage
  • H2020-EU.3.1.7.13. Other
    • H2020-JTI-IMI2-2014-02-single-stage
    • H2020-JTI-IMI2-2015-04-two-stage
  • H2020-EU.3.1.7.4. Diabetes
  • H2020-EU.3.1.7.5. Neurodegenerative diseases
  • H2020-EU.3.1.7.6. Psychiatric diseases
  • H2020-EU.3.1.7.8. Immune-mediated diseases
Powered by Chris Decubber BV